Focused On-demand Library for Serine racemase

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9GZT4

UPID:
SRR_HUMAN

ALTERNATIVE NAMES:
D-serine ammonia-lyase; D-serine dehydratase; L-serine ammonia-lyase; L-serine dehydratase

ALTERNATIVE UPACC:
Q9GZT4; D3DTI5; Q6IA55

BACKGROUND:
The enzyme Serine racemase, encompassing functions as D-serine dehydratase and L-serine ammonia-lyase, catalyzes the conversion of L-serine to D-serine. This process is essential for the production of D-serine, a significant coagonist with glutamate at NMDA receptors, implicating its importance in synaptic plasticity and neurotransmission. The enzyme's ability to act on both L-serine and D-serine as a dehydratase adds to its functional diversity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Serine racemase offers a promising avenue for the development of novel therapeutic approaches. Given its critical role in the biosynthesis of D-serine, a coagonist at NMDA receptors, targeting this enzyme could yield breakthroughs in treating neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8600 of 8789